Home Newsfeeds Mizuho Maintains Neutral on Squarespace, Raises Price Target to $26

Mizuho Maintains Neutral on Squarespace, Raises Price Target to $26

Mizuho analyst Siti Panigrahi maintains Squarespace (NYSE:SQSP) with a Neutral and raises the price target from $20 to $26.

byBenzinga Newsdesk

March 8, 2023

1 minute read

Mizuho analyst Siti Panigrahi maintains Squarespace (NYSE:SQSP) with a Neutral and raises the price target from $20 to $26.

Analyst Ratings

The Latest Analyst Ratings for Snowflake

By Benzinga Insights

June 21, 3:00 PM

Within the last quarter, Snowflake (NYSE:SNOW) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat Bearish…

SNOW

In-Depth Analysis: Procter & Gamble Versus Competitors In Household Products Industry

By Benzinga Insights

April 24, 11:01 AM

In today’s fast-paced and competitive business landscape, it is essential for investors and industry enthusiasts to thoroughly analyze…

Rockstar Upgrades Red Dead Redemption For One Video Game System, But What About Others?

By Franca Quarneti

October 5, 4:13 PM

Take-Two Interactive Software Inc.'s (NASDAQ: TTWO) Rockstar quietly added a 60 frames per second (fps) option to "Red Dead Redemption" on PlayStation 5, but players on other platforms are wondering when they'll

TTWO

Connect Biopharma Announces Long-Term Data From The Maintenance Period Through Week 48 Of CN002 Phase 2 Icanbelimod Trial In Patients With Moderate-To-Severe Ulcerative Colitis

By Happy Mohamed

June 1, 4:31 PM

Icanbelimod demonstrated sustained clinical remission, a regulatory relevant efficacy endpoint, through Week 48 in 80% of patients who achieved clinical remission at Week 12 of the induction

CNTB

Mizuho Maintains Neutral on Squarespace, Raises Price Target to $26

Related Posts

The Latest Analyst Ratings for Snowflake

In-Depth Analysis: Procter & Gamble Versus Competitors In Household Products Industry

Rockstar Upgrades Red Dead Redemption For One Video Game System, But What About Others?

Connect Biopharma Announces Long-Term Data From The Maintenance Period Through Week 48 Of CN002 Phase 2 Icanbelimod Trial In Patients With Moderate-To-Severe Ulcerative Colitis